In the "unlikely" event of a no-deal Brexit where the current regulatory arrangements between the UK and the EU would fall away, the UK government says it would unilaterally accept batch testing of approved and investigational medicines carried out in EU countries. In the meantime, life science companies have been asked to stockpile an additional six weeks' supply of medicines in the run up to the UK's departure from the EU at the end of March 2019 - "a massive challenge", according to one trade group.
The UK regulator, the MHRA, would assume the regulatory functions currently undertaken by the EU in areas such as new...








